Paladin Partners’s Viking Therapeutics VKTX Stock Holding History

Paladin Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.8K	Hold	200	–	–	0.01%	140
2026 Q1	$6.51K	Hold	200	–	–	﹤0.01%	141
2025 Q4	$7.04K	Buy	+200	New	+$7.09K	0.01%	138

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Paladin Partners's VKTX Position: Q2 2026 in Review

Paladin Partners held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 200 shares worth $7.8K. The position accounts for 0.01% of the portfolio, ranked #140.

Paladin Partners first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Paladin Partners held 200 shares of Viking Therapeutics worth $7.8K as of Q2 2026.
Paladin Partners left its Viking Therapeutics share count unchanged in Q2 2026.
Viking Therapeutics made up 0.01% of Paladin Partners's portfolio in Q2 2026, its #140 holding.
Paladin Partners first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.